Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial

Published in The Lancet Oncology · View the paper (DOI)

A clinical trial found that cetuximab was more effective than durvalumab in treating advanced squamous cell carcinoma of the head or neck, with a higher probability of being alive and free of disease at two years. Cetuximab's efficacy was similar whether or not the cancer was associated with HPV.

Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial

Coverage from 2 institutions